X-Chem, a provider of innovative solutions in early-stage drug discovery, announced executive management team changes aimed at expanding its position as a premium provider of integrated services to drug hunters.
Karen Lackey, currently Chief Scientific Officer, will transition to the role of Chief Executive Officer. Karen’s extensive drug discovery experience in both pharma and service organizations makes her the ideal leader to guide X-Chem into the next phase of its evolution. Under Karen’s leadership, X-Chem will continue innovating in data-accelerated drug discovery utilizing a unique combination of computational science and experimental data generation to catalyze a small molecule drug discovery revolution.
Current X-Chem Chief Executive Officer Matthew Clark will transition to the role of President and Chief Scientific Officer. In this role, Matt will focus on maintaining X-Chem’s edge in novel drug discovery technologies, ensuring X-Chem’s clients access a full range of innovative services to advance their pipelines. A drug discovery technology thought leader, Matt will continue to have a crucial role aligning X-Chem’s scientific capabilities to its corporate mission and clients’ needs.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!